Physician profile
Bryan E Steele
NPI 1053503045
$602.75
in general payments reported to CMS, 2019-2025
21 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $98.97 · 2021: $240 · 2022: $12.50 · 2023: $0.79 · 2024: $22.27 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.63 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $187.04 | 2021-2025 | |
| Hologic Sales and Service, LLC | $57.28 | 2020-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Pfizer INC. | $44.96 | 2019-2025 | |
| Dexcom, INC. | $38.79 | 2021 | |
| Agile Therapeutics, INC. | $26.19 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $26.13 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $24.45 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $19.82 | 2020 | |
| Optos, INC. | $18.89 | 2020 | |
| Vanda Pharmaceuticals INC. | $17.81 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.78 | 2019 | |
| Allergan, INC. | $15.63 | 2020 | |
| Amarin Pharma, INC. | $15.33 | 2019 | |
| Lilly USA, LLC | $14.67 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $13.99 | 2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $13.96 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.87 | 2021 | |
| Gilead Sciences, INC. | $12.61 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.92 | 2019 | |
| Merck Sharp & Dohme LLC | $10.84 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.